2026-07-07 エディンバラ大学
＜関連情報＞
- https://www.ed.ac.uk/news/hormone-differences-point-to-endometriosis-blood-test
- https://academic.oup.com/ejendo/article/195/1/22/8725815
ステロイドホルモンのプロファイリングにより、子宮内膜症における副腎アンドロゲン産生の変化が明らかになった Steroid hormone profiling reveals altered adrenal androgen production in endometriosis
Ioannis Simitsidellis,Rebecca J Ainslie,Angela E Taylor,Lorna C Gilligan,Fozia Shaheen,Samira Blanke,Craig Anderson,Dharani Hapangama,Wiebke Arlt,Andrew W Horne,…
European Journal of Endocrinology Published:07 July 2026
DOI:https://doi.org/10.1093/ejendo/lvag109
Abstract
Objective
Endometriosis is a chronic, hormone-dependent condition affecting an estimated 190 million women worldwide. Our understanding of hormonal contributions to endometriosis pathophysiology is incomplete, hindering the identification of diagnostic biomarkers and novel therapeutic targets. Although the role of estrogens is well established, research on androgens in endometriosis is limited and the contribution of adrenal-derived 11-oxygenated androgens remains largely unknown.
Methods
We performed steroid androgen profiling to measure androgen concentrations in serum from healthy controls and women with laparoscopically confirmed endometriosis. We found that women with endometriosis had a distinct hormone signature characterized by systemic differences in adrenal androgen concentrations and 11-ketotestosterone excess.
Using metabolomic data, we generated statistical models that showed robust discrimination between healthy controls and women with endometriosis (AUC = 0.99; positive predictive power = 96.84%, negative predictive power = 92.86%) consistent with an endometriosis-specific signature. Data were partitioned into train and validation groups to assess diagnostic potential and a refined model identified >95% of endometriosis patients in a blinded sample set.
Conclusions
Collectively, these data reframe endometriosis as an androgen-dependent disorder and highlight 11-oxygenated androgens as potential diagnostic biomarkers and future therapeutic targets.
